vTv Therapeutics (VTVT) Announces Earnings Results
vTv Therapeutics (NASDAQ:VTVT) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06, Fidelity Earnings reports. The company had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.06 million.
NASDAQ VTVT opened at $2.63 on Friday. vTv Therapeutics has a 12 month low of $0.65 and a 12 month high of $8.40. The stock has a market capitalization of $91.52 million, a price-to-earnings ratio of -1.57 and a beta of -3.71.
Separately, Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $13.29.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Featured Article: Bond
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.